Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Growth (Status and Outlook) 2022-2028
- LP 4894273
- 101 Pages
- March 2022
- Medical Devices
The United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market is expected at value of US$ million in 2021 and grow at approximately % CAGR during review period. China constitutes a % market for the global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market, reaching US$ million by the year 2028. As for the Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period. In APAC, the growth rates of other notable markets (Japan and South Korea) are projected to be at % and % respectively for the next 5-year period.
Global main Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics players cover Siemens Healthcare, Celerion, ZyVersa Therapeutics, Inc., and Cisbio, etc. In terms of revenue, the global largest two companies occupy a share nearly % in 2021.
This report presents a comprehensive overview, market shares, and growth opportunities of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics market by product type, application, key players and key regions and countries.
Segmentation by type: breakdown data from 2017 to 2022 in Section 2.3; and forecast to 2028 in section 10.7.
Therapeutics
Diagnostics
Segmentation by application: breakdown data from 2017 to 2022, in Section 2.4; and forecast to 2028 in section 10.8.
Hospital
Clinic
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Siemens Healthcare
Celerion
ZyVersa Therapeutics, Inc.
Cisbio
Regeneron Pharmaceuticals, Inc.
BioPredictive
Echosens
Genfit
Enterome
NGM Biopharmaceuticals
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2017-2028
2.1.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size CAGR by Region 2017 VS 2022 VS 2028
2.2 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Segment by Type
2.2.1 Therapeutics
2.2.2 Diagnostics
2.3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type
2.3.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size CAGR by Type (2017 VS 2022 VS 2028)
2.3.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Type (2017-2022)
2.4 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Segment by Application
2.4.1 Hospital
2.4.2 Clinic
2.5 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application
2.5.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size CAGR by Application (2017 VS 2022 VS 2028)
2.5.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Application (2017-2022)
3 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Player
3.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Players
3.1.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Players (2020-2022)
3.1.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Players (2020-2022)
3.2 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Regions
4.1 Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Regions (2017-2022)
4.2 Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth (2017-2022)
4.3 APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth (2017-2022)
4.4 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth (2017-2022)
4.5 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth (2017-2022)
5 Americas
5.1 Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2017-2022)
5.2 Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2017-2022)
5.3 Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2017-2022)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2017-2022)
6.2 APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2017-2022)
6.3 APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2017-2022)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Country (2017-2022)
7.2 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2017-2022)
7.3 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2017-2022)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics by Region (2017-2022)
8.2 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2017-2022)
8.3 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2017-2022)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecast by Regions (2023-2028)
10.1.1 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecast by Regions (2023-2028)
10.1.2 Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecast
10.1.3 APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecast
10.1.4 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecast
10.1.5 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecast
10.2 Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecast by Country (2023-2028)
10.2.1 United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.2.2 Canada Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.2.3 Mexico Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.2.4 Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.3 APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecast by Region (2023-2028)
10.3.1 China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.3.2 Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.3.3 Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.3.4 Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.3.5 India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.3.6 Australia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.4 Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecast by Country (2023-2028)
10.4.1 Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.4.2 France Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.4.3 UK Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.4.4 Italy Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.4.5 Russia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.5 Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecast by Region (2023-2028)
10.5.1 Egypt Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.5.2 South Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.5.3 Israel Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.5.4 Turkey Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.5.5 GCC Countries Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Forecast
10.6 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecast by Type (2023-2028)
10.7 Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Forecast by Application (2023-2028)
11 Key Players Analysis
11.1 Siemens Healthcare
11.1.1 Siemens Healthcare Company Information
11.1.2 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
11.1.3 Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
11.1.4 Siemens Healthcare Main Business Overview
11.1.5 Siemens Healthcare Latest Developments
11.2 Celerion
11.2.1 Celerion Company Information
11.2.2 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
11.2.3 Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
11.2.4 Celerion Main Business Overview
11.2.5 Celerion Latest Developments
11.3 ZyVersa Therapeutics, Inc.
11.3.1 ZyVersa Therapeutics, Inc. Company Information
11.3.2 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
11.3.3 ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
11.3.4 ZyVersa Therapeutics, Inc. Main Business Overview
11.3.5 ZyVersa Therapeutics, Inc. Latest Developments
11.4 Cisbio
11.4.1 Cisbio Company Information
11.4.2 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
11.4.3 Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
11.4.4 Cisbio Main Business Overview
11.4.5 Cisbio Latest Developments
11.5 Regeneron Pharmaceuticals, Inc.
11.5.1 Regeneron Pharmaceuticals, Inc. Company Information
11.5.2 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
11.5.3 Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
11.5.4 Regeneron Pharmaceuticals, Inc. Main Business Overview
11.5.5 Regeneron Pharmaceuticals, Inc. Latest Developments
11.6 BioPredictive
11.6.1 BioPredictive Company Information
11.6.2 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
11.6.3 BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
11.6.4 BioPredictive Main Business Overview
11.6.5 BioPredictive Latest Developments
11.7 Echosens
11.7.1 Echosens Company Information
11.7.2 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
11.7.3 Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
11.7.4 Echosens Main Business Overview
11.7.5 Echosens Latest Developments
11.8 Genfit
11.8.1 Genfit Company Information
11.8.2 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
11.8.3 Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
11.8.4 Genfit Main Business Overview
11.8.5 Genfit Latest Developments
11.9 Enterome
11.9.1 Enterome Company Information
11.9.2 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
11.9.3 Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
11.9.4 Enterome Main Business Overview
11.9.5 Enterome Latest Developments
11.10 NGM Biopharmaceuticals
11.10.1 NGM Biopharmaceuticals Company Information
11.10.2 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
11.10.3 NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue, Gross Margin and Market Share (2020-2022)
11.10.4 NGM Biopharmaceuticals Main Business Overview
11.10.5 NGM Biopharmaceuticals Latest Developments
12 Research Findings and Conclusion
Table 1. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size CAGR by Region (2017 VS 2022 VS 2028) & ($ Millions)
Table 2. Major Players of Therapeutics
Table 3. Major Players of Diagnostics
Table 4. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size CAGR by Type (2017 VS 2022 VS 2028) & ($ Millions)
Table 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2017-2022) & ($ Millions)
Table 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Type (2017-2022)
Table 7. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size CAGR by Application (2017 VS 2022 VS 2028) & ($ Millions)
Table 8. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2017-2022) & ($ Millions)
Table 9. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Application (2017-2022)
Table 10. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue by Players (2020-2022) & ($ Millions)
Table 11. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Player (2020-2022)
Table 12. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Key Players Head office and Products Offered
Table 13. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Concentration Ratio (CR3, CR5 and CR10) & (2020-2022)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Regions 2017-2022 & ($ Millions)
Table 17. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Regions (2017-2022)
Table 18. Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2017-2022) & ($ Millions)
Table 19. Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Country (2017-2022)
Table 20. Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2017-2022) & ($ Millions)
Table 21. Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Type (2017-2022)
Table 22. Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2017-2022) & ($ Millions)
Table 23. Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Application (2017-2022)
Table 24. APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2017-2022) & ($ Millions)
Table 25. APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Region (2017-2022)
Table 26. APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2017-2022) & ($ Millions)
Table 27. APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Type (2017-2022)
Table 28. APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2017-2022) & ($ Millions)
Table 29. APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Application (2017-2022)
Table 30. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Country (2017-2022) & ($ Millions)
Table 31. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Country (2017-2022)
Table 32. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2017-2022) & ($ Millions)
Table 33. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Type (2017-2022)
Table 34. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2017-2022) & ($ Millions)
Table 35. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Application (2017-2022)
Table 36. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Region (2017-2022) & ($ Millions)
Table 37. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Region (2017-2022)
Table 38. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Type (2017-2022) & ($ Millions)
Table 39. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Type (2017-2022)
Table 40. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size by Application (2017-2022) & ($ Millions)
Table 41. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Application (2017-2022)
Table 42. Key Market Drivers & Growth Opportunities of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
Table 43. Key Market Challenges & Risks of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
Table 44. Key Industry Trends of Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics
Table 45. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Regions (2023-2028) & ($ Millions)
Table 46. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share Forecast by Regions (2023-2028)
Table 47. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Type (2023-2028) & ($ Millions)
Table 48. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share Forecast by Type (2023-2028)
Table 49. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Forecast by Application (2023-2028) & ($ Millions)
Table 50. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share Forecast by Application (2023-2028)
Table 51. Siemens Healthcare Details, Company Type, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Area Served and Its Competitors
Table 52. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
Table 53. Siemens Healthcare Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 54. Siemens Healthcare Main Business
Table 55. Siemens Healthcare Latest Developments
Table 56. Celerion Details, Company Type, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Area Served and Its Competitors
Table 57. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
Table 58. Celerion Main Business
Table 59. Celerion Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 60. Celerion Latest Developments
Table 61. ZyVersa Therapeutics, Inc. Details, Company Type, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Area Served and Its Competitors
Table 62. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
Table 63. ZyVersa Therapeutics, Inc. Main Business
Table 64. ZyVersa Therapeutics, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 65. ZyVersa Therapeutics, Inc. Latest Developments
Table 66. Cisbio Details, Company Type, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Area Served and Its Competitors
Table 67. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
Table 68. Cisbio Main Business
Table 69. Cisbio Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 70. Cisbio Latest Developments
Table 71. Regeneron Pharmaceuticals, Inc. Details, Company Type, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Area Served and Its Competitors
Table 72. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
Table 73. Regeneron Pharmaceuticals, Inc. Main Business
Table 74. Regeneron Pharmaceuticals, Inc. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 75. Regeneron Pharmaceuticals, Inc. Latest Developments
Table 76. BioPredictive Details, Company Type, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Area Served and Its Competitors
Table 77. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
Table 78. BioPredictive Main Business
Table 79. BioPredictive Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 80. BioPredictive Latest Developments
Table 81. Echosens Details, Company Type, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Area Served and Its Competitors
Table 82. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
Table 83. Echosens Main Business
Table 84. Echosens Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 85. Echosens Latest Developments
Table 86. Genfit Details, Company Type, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Area Served and Its Competitors
Table 87. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
Table 88. Genfit Main Business
Table 89. Genfit Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 90. Genfit Latest Developments
Table 91. Enterome Details, Company Type, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Area Served and Its Competitors
Table 92. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
Table 93. Enterome Main Business
Table 94. Enterome Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 95. Enterome Latest Developments
Table 96. NGM Biopharmaceuticals Details, Company Type, Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Area Served and Its Competitors
Table 97. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Product Offered
Table 98. NGM Biopharmaceuticals Main Business
Table 99. NGM Biopharmaceuticals Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue ($ million), Gross Margin and Market Share (2020-2022)
Table 100. NGM Biopharmaceuticals Latest Developments
List of Figures
Figure 1. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth Rate 2017-2028 ($ Millions)
Figure 6. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Type in 2021
Figure 7. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics in Hospital
Figure 8. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market: Hospital (2017-2022) & ($ Millions)
Figure 9. Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics in Clinic
Figure 10. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market: Clinic (2017-2022) & ($ Millions)
Figure 11. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Application in 2021
Figure 12. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Revenue Market Share by Player in 2021
Figure 13. Global Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Regions (2017-2022)
Figure 14. Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2017-2022 ($ Millions)
Figure 15. APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2017-2022 ($ Millions)
Figure 16. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2017-2022 ($ Millions)
Figure 17. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2017-2022 ($ Millions)
Figure 18. Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Value Market Share by Country in 2021
Figure 19. Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Consumption Market Share by Type in 2021
Figure 20. Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Application in 2021
Figure 21. United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 22. Canada Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 23. Mexico Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 24. Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 25. APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Region in 2021
Figure 26. APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Application in 2021
Figure 27. China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 28. Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 29. Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 30. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 31. India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 32. Australia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 33. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Country in 2021
Figure 34. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Type in 2021
Figure 35. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Application in 2021
Figure 36. Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 37. France Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 38. UK Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 39. Italy Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 40. Russia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 41. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Region in 2021
Figure 42. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Type in 2021
Figure 43. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Market Share by Application in 2021
Figure 44. Egypt Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 45. South Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 46. Israel Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 47. Turkey Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 48. GCC Country Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size Growth 2017-2022 ($ Millions)
Figure 49. Americas Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 50. APAC Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 51. Europe Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 52. Middle East & Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 53. United States Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 54. Canada Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 55. Mexico Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 56. Brazil Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 57. China Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 58. Japan Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 59. Korea Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 60. Southeast Asia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 61. India Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 62. Australia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 63. Germany Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 64. France Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 65. UK Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 66. Italy Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 67. Russia Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 68. Spain Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 69. Egypt Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 70. South Africa Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 71. Israel Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 72. Turkey Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Figure 73. GCC Countries Non-Alcoholic Steatohepatitis (NASH) Therapeutics and Diagnostics Market Size 2023-2028 ($ Millions)
Similar Reports
This report provides an overview of the French molecular diagnostic testing market, including test volume, and sales forecasts by Application, 2019-2023, and supplier shares by test.
Table of Contents
Business Environment
Market Structure
Market Size, Growth, and Major Suppliers' Market Shares
This report provides an overview of the German molecular diagnostic testing market, including test volume, and sales forecasts by application, and supplier shares by test.
Table of Contents
Business Environment
Market Structure
Market Size, Growth, and Major Suppliers' Market Shares
&nb...
- Publish Date: April 1, 2019
- $450
This report provides an overview of the Italian molecular diagnostic testing market, including test volume, and sales forecasts by application, and supplier shares by test.
Table of Contents
Business Environment
Market Structure
Market Size, Growth, and Major Suppliers' Market Shares
&nb...
- Publish Date: April 1, 2019
- $450
